We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Nanofluidic Device Traps and Concentrates Pathogenic Bacteria

By LabMedica International staff writers
Posted on 31 Mar 2020
A nanofluidic device containing stacked magnetic beads of different sizes has been developed to efficiently trap, concentrate, and retrieve Escherichia coli (E. More...
coli) bacteria from liquid suspensions.

The miniaturized, inexpensive, and transparent device developed by investigators at Rutgers University (Rochester, NY, USA) and the Rochester Institute of Technology (NY, USA) is easy to fabricate and operate, making it ideal for pathogen separation in both laboratory and point-of-care settings.

The investigators used computational fluid dynamics, three-dimensional tomography technology, and machine learning to probe and explain the effects of bead stacking in a small three-dimensional space with various flow rates. Ultimately, a combination of beads with different sizes was utilized to achieve a high capture efficiency (approximately 86%) with a flow rate of 50 microliters per minute.

In addition, the investigators showed that the high deformability of the device enabled retrieval of an E. coli sample from a bacterial suspension by applying a higher flow rate followed by rapid magnetic separation. This unique function was also utilized to concentrate E. coli cells from the original bacterial suspension. An on-chip concentration factor of about 11 times was achieved by inputting 1300 microliters of the E. coli sample and then concentrating it down to 100 microliters.

The new device is expected to play an important role in the identification and isolation of drug resistant strains of bacteria, from which at least 700,000 people die each year, including 230,000 deaths from multidrug-resistant tuberculosis.

"The rapid identification of drug-resistant bacteria allows health care providers to prescribe the right drugs, boosting the chances of survival," said contributing author Dr. Ruo-Qian (Roger) Wang, assistant professor of civil and environmental engineering at Rutgers University.

The nanofluidic device was described in the February 19, 2020, issue of the journal ACS Applied Materials & Interfaces.

Related Links:
Rutgers University
Rochester Institute of Technology



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Immunoblots Processor
BlueDiver Instrument II
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The partnership with LLS expands access to Lucent’s non-invasive blood-based biomarker tests for early detection of cognitive diseases (photo courtesy of Adobe Stock)

New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network

Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.